Online citations, reference lists, and bibliographies.
← Back to Search

Circulating TIMP-1 Is Associated With Hematoma Volume In Patients With Spontaneous Intracranial Hemorrhage

M. Navarro-Oviedo, R. Muñoz-Arrondo, B. Zandio, J. Marta-Enguita, Anna Bonaterra-Pastra, J. Rodríguez, C. Roncal, J. Paramo, E. Toledo, J. Montaner, M. Hernández-Guillamon, J. Orbe
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Matrix metalloproteinases (MMPs) are proteolytic zinc-endopeptidases regulated by tissue Inhibitors of matrix metalloproteinases (TIMPs). We evaluated the potential of MMPs and TIMPs as clinical tools for Intracranial Haemorrhage (ICH). Spontaneous non‐traumatic ICH patients were recruited from two hospitals: Complejo Hospitalario de Navarra (CHN = 29) and Vall d´Hebron (VdH = 76). Plasmatic levels of MMP-1, −2, −7, −9, −10 and TIMP-1 and their relationship with clinical, radiological and functional variables were evaluated. We further studied the effect of TIMP-1 (0.05–0.2 mg/Kg) in an experimental tail-bleeding model. In CHN, TIMP-1 was associated with admission-hematoma volume and MMP-7 was elevated in patients with deep when compared to lobar hematoma. In VdH, admission-hematoma volume was associated with TIMP-1 and MMP-7. When data from both hospitals were combined, we observed that an increase in 1 ng/ml in TIMP-1 was associated with an increase of 0.14 ml in haemorrhage (combined β = 0.14, 95% CI = 0.08–0.21). Likewise, mice receiving TIMP-1 (0.2 mg/Kg) showed a shorter bleeding time (p < 0.01). Therefore, the association of TIMP-1 with hematoma volume in two independent ICH cohorts suggests its potential as ICH biomarker. Moreover, increased TIMP-1 might not be sufficient to counterbalance MMPs upregulation indicating that TIMP-1 administration might be a beneficial strategy for ICH.
This paper references
10.4315/0362-028X-47.2.145
An Update.
K. Johnson (1984)
10.1097/00006123-199709000-00027
Matrix metalloproteinase-9 in cerebral aneurysms.
S. Kim (1997)
Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery
Kim (1997)
10.1038/sj.ijo.0801992
A 12-year follow-up study of treated obese children in Japan
K. Togashi (2002)
10.1016/S0092-8674(02)01079-6
Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury
Qinglang Li (2002)
10.3171/JNS.2003.99.1.0065
Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage.
S. Abilleira (2003)
10.1212/WNL.60.1.52
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
E. Waubant (2003)
10.1163/9789401206112_003
Second Edition
John Wang Montclair (2004)
10.1161/01.STR.0000126827.69286.90
Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage: Relationship to Clinical and Radiological Outcome
J. Álvarez-Sabín (2004)
Handbook of Proteolytic Enzymes: Second Edition. Handbook of Proteolytic Enzymes: Second Edition
A J Barrett (2004)
10.1002/glia.20169
Multiple roles for MMPs and TIMPs in cerebral ischemia
L. A. Cunningham (2005)
10.1016/J.AHJ.2004.11.016
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
J. George (2005)
10.1161/01.STR.0000198806.67472.5C
Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage.
H. Huttner (2006)
10.1016/j.nbd.2005.09.007
In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation
J. Sellner (2006)
10.1038/sj.gt.3302894
Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and -2 in ischemic brain injury
S. Magnoni (2007)
10.1038/jcbfm.2008.59
Tissue Inhibitor of Metalloproteinases Protect Blood—Brain Barrier Disruption in Focal Cerebral Ischemia
M. Fujimoto (2008)
10.1016/j.bbamcr.2010.01.003
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.
K. Brew (2010)
An ancient family with structural and functional diversity
K. Brew (2010)
10.1177/1941875211409050
Update in Intracerebral Hemorrhage
M. Aguilar (2011)
Update in Intracerebral Hemorrhage. The Neurohospitalist
M I Aguilar (2011)
The EURODIAB Prospective Complications Study
G. Gruden (2012)
10.1111/j.1750-3639.2011.00512.x
MMP‐2/MMP‐9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathy‐Associated Hemorrhagic Stroke
M. Hernández-Guillamon (2012)
10.1159/000341686
Matrix Metalloproteinases in Human Spontaneous Intracerebral Hemorrhage: An Update
M. Florczak-Rzepka (2012)
10.1371/journal.pone.0059952
Differential Regulation of Matrix-Metalloproteinases and Their Tissue Inhibitors in Patients with Aneurysmal Subarachnoid Hemorrhage
M. Fischer (2013)
10.1161/STROKEAHA.112.673590
Association of Molecular Markers With Perihematomal Edema and Clinical Outcome in Intracerebral Hemorrhage
N. Li (2013)
10.1007/s00125-013-3052-4
Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients
M. Toni (2013)
10.1371/journal.pone.0094370
Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury
L. Lorente (2014)
10.1016/j.jphys.2013.12.012
National Institutes of Health Stroke Scale (NIHSS).
L. Kwah (2014)
10.1001/jama.2015.10082
Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
A. Biffi (2015)
10.1186/s12883-015-0364-7
Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction
L. Lorente (2015)
10.1186/s12933-015-0195-2
Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
S. A. Peeters (2015)
10.3233/JAD-143186
Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
F. Duits (2015)
10.1016/j.brainres.2015.04.024
Matrix metalloproteinases as therapeutic targets for stroke
Y. Yang (2015)
10.1038/nrneurol.2014.264
Targeting secondary injury in intracerebral haemorrhage—perihaematomal oedema
Sebastian Urday (2015)
10.1016/j.neurobiolaging.2015.07.016
Matrix metalloproteinase 9–mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy
Lingzhi Zhao (2015)
10.3389/fneur.2015.00121
Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict Hemorrhagic Transformation of Lesion in Ischemic Stroke Patients Treated with Thrombolysis: Results from the MAGIC Study
B. Piccardi (2015)
10.1021/jm501940y
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
J. Orbe (2015)
10.1161/STROKEAHA.117.017866
Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.
J. Broderick (2017)
Elevated MMP-1 and TIMP-1 are related with acute cerebral infarction patients with diabetes mellitus
Jin-xia Zhang (2017)
10.1186/s12933-017-0539-1
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
S. A. Peeters (2017)
10.1161/JAHA.117.006042
CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage
J. Rodríguez (2017)
10.1016/j.nic.2018.03.003
Approach to Imaging in Patients with Spontaneous Intracranial Hemorrhage.
P. Kranz (2018)
10.1212/WNL.0000000000006117
Assessment and comparison of the max-ICH score and ICH score by external validation
F. Schmidt (2018)
10.3389/fneur.2018.00746
Serum Markers of Blood-Brain Barrier Remodeling and Fibrosis as Predictors of Etiology and Clinicoradiologic Outcome in Intracerebral Hemorrhage
Matthew D. Howe (2018)
10.1161/STROKEAHA.118.020660
High Serum Level of Matrix Metalloproteinase-7 Is Associated With Increased Risk of Spontaneous Subarachnoid Hemorrhage
Martin Söderholm (2018)
10.1161/STROKEAHA.117.019541
Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage.
M. Selim (2018)
10.1080/02688697.2018.1427213
Association of functional MMP-2 gene variant with intracranial aneurysms: case-control genetic association study and meta-analysis
V. Alg (2018)
10.1016/S1474-4422(18)30253-9
Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data
R. Al‐Shahi Salman (2018)
10.1016/j.atherosclerosis.2018.09.022
Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification.
A. Purroy (2018)
Assessment and comparison of the max-ICH score and ICH score by external validation. Neurology
F. A. Schmidt (2018)
a systematic review and meta-analysis of individual patient data
Al-Shahi Salman (2018)
case-control genetic association study and meta-analysis
Alg (2018)
10.1016/S1474-4422(19)30043-2
Stroke genetics: discovery, biology, and clinical applications
M. Dichgans (2019)
10.1097/CNQ.0000000000000247
Acute Management of Hypertension Following Intracerebral Hemorrhage
J. Haller (2019)
10.1016/S0140-6736(19)30195-3
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
D. Hanley (2019)
10.1016/j.jcrc.2019.02.014
Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients.
L. Lorente (2019)
10.1016/j.wneu.2019.10.106
High serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with spontaneous intracerebral hemorrhage.
L. Lorente (2019)
10.1177/1747493019839280
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III)
W. Ziai (2019)
10.1177/1747493019830589
Location-specific differences in hematoma volume predict outcomes in patients with spontaneous intracerebral hemorrhage
N. Ironside (2019)
10.12659/MSM.908500
Matrix Metalloproteases-Mediated Cleavage on β-Dystroglycan May Play a Key Role in the Blood–Brain Barrier After Intracerebral Hemorrhage in Rats
X. Zhang (2019)
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label
D F Hanley (2019)
a randomised, controlled, open-label, blinded endpoint phase 3 trial
Hanley (2019)
discovery, biology, and clinical applications
M. Dichgans (2019)
Results from the MAGIC study
Piccardi (2020)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar